Cargando…

Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes

Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS). Objective and Methods: The sNfL levels and MOG-Abs were measured by...

Descripción completa

Detalles Bibliográficos
Autores principales: Simone, Marta, Palazzo, Claudia, Mastrapasqua, Mariangela, Bollo, Luca, Pompamea, Francesco, Gabellone, Alessandra, Marzulli, Lucia, Giordano, Paola, De Giacomo, Andrea, Frigeri, Antonio, Ruggieri, Maddalena, Margari, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635987/
https://www.ncbi.nlm.nih.gov/pubmed/34867740
http://dx.doi.org/10.3389/fneur.2021.754518
_version_ 1784608439659397120
author Simone, Marta
Palazzo, Claudia
Mastrapasqua, Mariangela
Bollo, Luca
Pompamea, Francesco
Gabellone, Alessandra
Marzulli, Lucia
Giordano, Paola
De Giacomo, Andrea
Frigeri, Antonio
Ruggieri, Maddalena
Margari, Lucia
author_facet Simone, Marta
Palazzo, Claudia
Mastrapasqua, Mariangela
Bollo, Luca
Pompamea, Francesco
Gabellone, Alessandra
Marzulli, Lucia
Giordano, Paola
De Giacomo, Andrea
Frigeri, Antonio
Ruggieri, Maddalena
Margari, Lucia
author_sort Simone, Marta
collection PubMed
description Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS). Objective and Methods: The sNfL levels and MOG-Abs were measured by ultrasensitive single-molecule array and cell-based assay in a cohort of 37 children with ADS and negativity for serum anti-aquaporin 4 (AQP4) antibodies. The sNfL levels were compared in MOG-Ab+/MOG-Ab– and in two subgroups MOG-Ab+ with/without encephalopathy. Results: About 40% ADS resulted in MOG-Ab+. MOG-Ab+ were younger at sampling (median = 9.8; range = 2.17–17.5 vs. 14.7/9–17; p = 0.002) with lower frequency of cerebrospinal fluid oligoclonal bands positivity (27% vs. 70%; p = 0.013) compared to MOG-Ab–. About 53% of MOG-Ab+ presented encephalopathy at onset, 1/22 of MOG-Ab– (p = 0.0006). Higher sNfL levels (p = 0.0001) were found in MOG-Ab+ (median/range = 11.11/6.8–1,129) and MOG-Ab– (median/range = 11.6/4.3–788) compared to age-matched controls (median/range = 2.98/1–4.53), without significant difference. MOG-Ab+ with encephalopathy resulted significantly younger at sampling (median/range: 4.5/2.17–11.17 vs. 14.16/9.8–17.5; p = 0.004), had higher sNfL levels (median/range:75.24/9.1–1,129 vs. 10.22/6.83–50.53; p = 0.04), and showed a trend for higher MOG-Ab titer (0.28/0.04–0.69 vs. 0.05/0.04–0.28; p = 0.1) in comparison to those without encephalopathy. Discussion: We confirmed high sNfL levels in pediatric ADS independently from the MOG-Ab status. Encephalopathy at onset is associated more frequently with MOG Ab+ children with higher sNfL levels and MOG titer. These findings suggest a role of acute demyelination in association with axonal damage in the pathogenesis of encephalopathy in pediatric ADS.
format Online
Article
Text
id pubmed-8635987
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86359872021-12-02 Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes Simone, Marta Palazzo, Claudia Mastrapasqua, Mariangela Bollo, Luca Pompamea, Francesco Gabellone, Alessandra Marzulli, Lucia Giordano, Paola De Giacomo, Andrea Frigeri, Antonio Ruggieri, Maddalena Margari, Lucia Front Neurol Neurology Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS). Objective and Methods: The sNfL levels and MOG-Abs were measured by ultrasensitive single-molecule array and cell-based assay in a cohort of 37 children with ADS and negativity for serum anti-aquaporin 4 (AQP4) antibodies. The sNfL levels were compared in MOG-Ab+/MOG-Ab– and in two subgroups MOG-Ab+ with/without encephalopathy. Results: About 40% ADS resulted in MOG-Ab+. MOG-Ab+ were younger at sampling (median = 9.8; range = 2.17–17.5 vs. 14.7/9–17; p = 0.002) with lower frequency of cerebrospinal fluid oligoclonal bands positivity (27% vs. 70%; p = 0.013) compared to MOG-Ab–. About 53% of MOG-Ab+ presented encephalopathy at onset, 1/22 of MOG-Ab– (p = 0.0006). Higher sNfL levels (p = 0.0001) were found in MOG-Ab+ (median/range = 11.11/6.8–1,129) and MOG-Ab– (median/range = 11.6/4.3–788) compared to age-matched controls (median/range = 2.98/1–4.53), without significant difference. MOG-Ab+ with encephalopathy resulted significantly younger at sampling (median/range: 4.5/2.17–11.17 vs. 14.16/9.8–17.5; p = 0.004), had higher sNfL levels (median/range:75.24/9.1–1,129 vs. 10.22/6.83–50.53; p = 0.04), and showed a trend for higher MOG-Ab titer (0.28/0.04–0.69 vs. 0.05/0.04–0.28; p = 0.1) in comparison to those without encephalopathy. Discussion: We confirmed high sNfL levels in pediatric ADS independently from the MOG-Ab status. Encephalopathy at onset is associated more frequently with MOG Ab+ children with higher sNfL levels and MOG titer. These findings suggest a role of acute demyelination in association with axonal damage in the pathogenesis of encephalopathy in pediatric ADS. Frontiers Media S.A. 2021-11-11 /pmc/articles/PMC8635987/ /pubmed/34867740 http://dx.doi.org/10.3389/fneur.2021.754518 Text en Copyright © 2021 Simone, Palazzo, Mastrapasqua, Bollo, Pompamea, Gabellone, Marzulli, Giordano, De Giacomo, Frigeri, Ruggieri and Margari. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Simone, Marta
Palazzo, Claudia
Mastrapasqua, Mariangela
Bollo, Luca
Pompamea, Francesco
Gabellone, Alessandra
Marzulli, Lucia
Giordano, Paola
De Giacomo, Andrea
Frigeri, Antonio
Ruggieri, Maddalena
Margari, Lucia
Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
title Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
title_full Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
title_fullStr Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
title_full_unstemmed Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
title_short Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
title_sort serum neurofilament light chain levels and myelin oligodendrocyte glycoprotein antibodies in pediatric acquired demyelinating syndromes
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635987/
https://www.ncbi.nlm.nih.gov/pubmed/34867740
http://dx.doi.org/10.3389/fneur.2021.754518
work_keys_str_mv AT simonemarta serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT palazzoclaudia serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT mastrapasquamariangela serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT bolloluca serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT pompameafrancesco serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT gabellonealessandra serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT marzullilucia serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT giordanopaola serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT degiacomoandrea serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT frigeriantonio serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT ruggierimaddalena serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes
AT margarilucia serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes